Camurati-Engelmann disease:: review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatment

被引:156
作者
Janssens, K
Vanhoenacker, F
Bonduelle, M
Verbruggen, L
Van Maldergem, L
Ralston, S
Guañabens, N
Migone, N
Wientroub, S
Divizia, MT
Bergmann, C
Bennett, C
Simsek, S
Melançon, S
Cundy, T
Van Hul, W
机构
[1] Univ Antwerp, Dept Med Genet, B-2610 Antwerp, Belgium
[2] Univ Antwerp Hosp, Dept Med Genet, Antwerp, Belgium
[3] Univ Hosp Brussels, Dept Med Genet, Brussels, Belgium
[4] Univ Hosp Brussels, Dept Rheumatol, Brussels, Belgium
[5] Inst Pathol & Genet, Ctr Human Genet, Loverval, Belgium
[6] Univ Edinburgh, Rheumat Dis Unit, Edinburgh, Midlothian, Scotland
[7] Hosp Clin Barcelona, Dept Rheumatol, E-08036 Barcelona, Spain
[8] Univ Turin, Dept Genet Biol & Biochem, Turin, Italy
关键词
D O I
10.1136/jmg.2005.033522
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Camurati- Engelmann disease ( CED) is a rare autosomal dominant type of bone dysplasia. This review is based on the unpublished and detailed clinical, radiological, and molecular findings in 14 CED families, comprising 41 patients, combined with data from 10 other previously reported CED families. For all 100 cases, molecular evidence for CED was available, as a mutation was detected in TGFB1, the gene encoding transforming growth factor ( TGF) beta 1. Pain in the extremities was the most common clinical symptom, present in 68% of the patients. A waddling gait ( 48%), easy fatigability ( 44%), and muscle weakness ( 39%) were other important features. Radiological symptoms were not fully penetrant, with 94% of the patients showing the typical long bone involvement. A large percentage of the patients also showed involvement of the skull ( 54%) and pelvis ( 63%). The review provides an overview of possible treatments, diagnostic guidelines, and considerations for prenatal testing. The detailed description of such a large set of CED patients will be of value in establishing the correct diagnosis, genetic counselling, and treatment.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 70 条
  • [51] ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419
  • [52] Domain-specific mutations of a transforming growth factor (TGF)-β1 latency-associated peptide cause Camurati-Engelmann disease because of the formation of a constitutively active form of TGF-β1
    Saito, T
    Kinoshita, A
    Yoshiura, K
    Makita, Y
    Wakui, K
    Honke, K
    Niikawa, N
    Taniguchi, N
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (15) : 11469 - 11472
  • [53] Saraiva JM, 1997, AM J MED GENET, V71, P348, DOI 10.1002/(SICI)1096-8628(19970822)71:3<348::AID-AJMG17>3.0.CO
  • [54] 2-K
  • [55] Dexamethasone reverses TGF-β-mediated inhibition of primary rat preadipocyte differentiation
    Shin, SM
    Kim, KY
    Kim, JK
    Yoon, SR
    Choi, I
    Yang, Y
    [J]. FEBS LETTERS, 2003, 543 (1-3) : 25 - 30
  • [56] The analgesic role of calcitonin following osteoporotic fracture
    Silverman, SL
    Azria, M
    [J]. OSTEOPOROSIS INTERNATIONAL, 2002, 13 (11) : 858 - 867
  • [57] Camurati-Engelmann disease (progressive diaphyseal dysplasia) in a Moroccan family
    Simsek, S
    Janssens, K
    Kwee, ML
    Van Hul, W
    Veenstra, J
    Netelenbos, JC
    [J]. OSTEOPOROSIS INTERNATIONAL, 2005, 16 (09) : 1167 - 1170
  • [58] SMITH R, 1977, Q J MED, V46, P273
  • [59] Glucocorticoid receptor inhibits transforming growth factor-β signaling by directly targeting the transcriptional activation function of Smad3
    Song, CZ
    Tian, X
    Gelehrter, TD
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (21) : 11776 - 11781
  • [60] CAMURATI-ENGELMANN DISEASE - GENETICS AND CLINICAL MANIFESTATIONS WITH A REVIEW OF LITERATURE
    SPARKES, RS
    GRAHAM, CB
    [J]. JOURNAL OF MEDICAL GENETICS, 1972, 9 (01) : 73 - &